Ole‐Petter R. Hamnvik

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Ole‐Petter R. Hamnvik, Toni K. Choueiri, Alexander Turchin et al. · Cancer · 2014 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma

Rana R. McKay, Gustavo E. Rodriguez, Xun Lin et al. · Clinical Cancer Research · 2015 · 136 citations · Full text

Medicine, Oncology, Pharmacology +15

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy

Maxine Sun, Toni K. Choueiri, Ole‐Petter R. Hamnvik et al. · JAMA Oncology · 2015 · 120 citations · Full text

Medicine, Oncology, Surgery +17

Morbidity and mortality in patients with craniopharyngioma after surgery

Rachel Crowley, Ole‐Petter R. Hamnvik, E. P. O’Sullivan et al. · Clinical Endocrinology · 2010 · 106 citations · Full text

Medicine, Oncology, Surgery +14

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

Dorothee M. Baur, Jens Klotsche, Ole‐Petter R. Hamnvik et al. · Metabolism · 2010 · 89 citations · Full text

Medicine, Internal Medicine, Oncology +9